Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.

Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.

http://www.wikidata.org/entity/Q37914630

about

Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling β-Catenin loss in hepatocytes promotes hepatocellular cancer after diethylnitrosamine and phenobarbital administration to mice.Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway.Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo.Increased liver carcinogenesis and enrichment of stem cell properties in livers of Dickkopf 2 (Dkk2) deleted mice.Newer treatments for advanced hepatocellular carcinoma.Pathways and targets in hepatocellular carcinoma.Prevention of recurrence after curative treatment for hepatocellular carcinoma.Plasma membrane gp96 enhances invasion and metastatic potential of liver cancer via regulation of uPAR Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy.Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience.Ursolic Acid-Induced Apoptosis via Regulation of the PI3K/Akt and MAPK Signaling Pathways in Huh-7 Cells

P2860

Q33718695-414E4358-D3AA-4628-9185-43D9438B4494 Q34326514-6B906ABC-62CB-409D-A531-F92AF9117C05 Q34483561-1FB082FC-FB06-4E04-9BC3-68D1AB689781 Q34531550-5BC6A12B-5AD5-4115-B0F1-8AB29682D0E5 Q37301702-609D6F79-AF54-48A2-A6C3-C358148EB3EB Q37642185-0C0BCF37-7B2D-4FB4-89EA-F1F2B905E09F Q38062022-E1EC3352-F81B-41C7-A67B-8406325C33D9 Q38070128-0588A662-36AD-4765-897F-7B0C2281E3F5 Q38891038-0700AF1C-3923-4320-A299-B4DFA503B0DE Q39929763-8791548D-4116-4AB4-AA7A-9CB7679B7F32 Q41623567-03974E5D-9EDE-43E5-BE46-AA3CF43D54A4 Q43047099-5704DB52-DCE9-4330-8D81-27625CEC7F78 Q51285944-53BCC021-A915-46DE-8FDA-4D5E0721F62B Q58697443-2A3C1F4D-C533-4630-9D04-2E37FAFD1CAD

P2860

Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.

http://www.wikidata.org/entity/Q37914630

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.

@en

Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.

@nl

type

label

Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.

@en

Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.

@nl

prefLabel

Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.

@en

Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.

@nl

P1433

Q37914630-1C000BA0-C527-4F5E-A824-8DA3FBC5EE91

P1476

Q37914630-600BCE94-5607-49AC-9704-D9072BD7AAB0

P2860

Q37914630-040E42AF-B1F2-4928-BF91-B6D39FA470B8

Q37914630-06E419AE-7A92-4E82-B73D-5A48AB0A375B

Q37914630-0C3394E3-556D-4B63-AFFD-62090B84B495

Q37914630-245F15A2-1D74-4BD0-8CE5-E34AD1F58659

Q37914630-29701337-54FB-4D89-B36D-4329623AFA44

Q37914630-2ACD64F5-06C3-4B69-9FA5-FD3E3324E9D5

Q37914630-32F0E4D8-1173-4F23-87B5-5559524338BC

Q37914630-3559052C-E5CA-49A3-B208-AD80EC5AABC4

Q37914630-3731FAE9-CE76-4409-BBC1-880678343A59

Q37914630-3A8DC62C-196E-4E5C-8E23-9BEAA6EC9E61

P304

Q37914630-7C73606E-7118-417D-AB33-E67E3268533A

P31

Q37914630-5A50EB65-8EEB-4BC7-91D6-535A2C347672

P356

Q37914630-25AF6BA5-A5A2-4858-A082-242D3779E102

P433

Q37914630-D02C0509-527E-4272-894A-53DA46D7CEE1

P478

Q37914630-5B61C80E-2D15-4A59-ABE0-D5EA1DD9E6B3

P50

Q37914630-C28A8E50-DA9A-4910-9D8B-5EEE4496B73F

P577

Q37914630-FCFF13E0-5BB1-42BA-95A5-B7E466A4CB09

P698

Q37914630-C5C9D648-6FA0-40F0-A769-051F262A713B

P356

P1433

Digestive Diseases

P1476

Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.

@en

P2860

The Hallmarks of Cancer

Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

Sorafenib in advanced hepatocellular carcinoma

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Hepatocellular carcinoma pathogenesis: from genes to environment

The biology of vascular endothelial growth factor

EGFR antagonists in cancer treatment

P304

289-302

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000327562

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21829020

http://www.w3.org/2001/XMLSchema#string